Compare Sanofi SA (SNY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Visa Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Visa Inc trades at $356.1 (market cap $685.71B). The key difference: Visa Inc is far larger — about 6.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | V | |
|---|---|---|
Market Cap | $104.83B | $685.71B |
Sector | Health | Financials |
52-Week High | $52.34 | $365.14 |
52-Week Low | $41.33 | $295.52 |
Enterprise Value | $121.32B | $696.30B |
Dividend Yield | 5.5% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
